EUVIMEDEUVIMED entdecken
Crossref

Limited Benefit of Bone Marrow Biopsy in Extranodal NK/T-Cell Lymphoma in the PET/CT Era

Hailing Liu, Yuxiao Zhao, Xiran Wang, Lvwen Chen, Chongyang Ding, Rong Wang, Yi Miao, Huayuan Zhu, Jianyong Li, Lei Cao, Lei Fan

Academic Radiology · 2025

DOI: 10.1016/j.acra.2025.09.024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Academic Radiology, 2025. Verfasst von Hailing Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Jiangsu Province Hospital, the First Affiliated Hospital With Nanjing Medical University, Nanjing 210029, Jiangsu, China (H…. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Lymphoma, Extranodal NK-T-Cell, Bone Marrow. Die Arbeit nennt 33 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province, Nanjing Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RATIONALE AND OBJECTIVES: Positron emission tomography/computed tomography (PET/CT) is central to lymphoma staging, yet current guidelines still mandate bone marrow biopsy (BMB) for histologically confirming bone marrow infiltration (BMI, which defines stage IV disease) in the initial staging of extranodal NK/T-cell lymphoma (ENKTL). This study aims to compare the diagnostic accuracy and prognostic value of PET/CT and BMB in detecting BMI, and to evaluate whether BMB can be omitted in certain subgroups to refine staging protocols and avoid invasive procedures. MATERIALS AND METHODS: We conducted a retrospective cohort study of 133 treatment-naïve ENKTL patients who underwent concurrent PET/CT and BMB. RESULTS: BMB results were negative in all PET/CT-defined localized-stage patients (n=88) but positive in 15.6% (7/45) of advanced-stage cases. Using BMB as the reference standard, PET/CT showed high sensitivity (85.7%) and negative predictive value (NPV=98.9%), supporting disease exclusion. Specificity was 73.8%, accuracy 74.4%. In advanced disease, sensitivity remained 85.7%, NPV 95.7%, but specificity declined to 57.9%. Prognostically, PET/CT-defined BMI predicted inferior progression-free survival (PFS, hazard ratio [HR]=2.36, P=0.036) and overall survival (OS, HR=3.3, P=0.026), whereas BMB positivity showed limited prognostic discrimination (PFS HR=1.7, P=0.293; OS HR=3.08, P=0.039). Time-dependent area under the curve analysis demonstrated that PET/CT-detected BMI had consistent superiority in prognostic prediction across all follow-up intervals, a finding further substantiated by its higher C-index values for both PFS (0.63 vs. 0.55) and OS (0.69 vs. 0.60) compared to BMB. Notably, BMB results did not alter early/advanced staging or treatment allocation, but showed significant association with hemophagocytic lymphohistiocytosis (85.7% vs. 28.9%, P=0.015). CONCLUSION: PET/CT demonstrates high diagnostic and prognostic value in ENKTL staging, supported by an NPV of 98.9% and general alignment with therapeutic decision-making. Thus, routine BMB could potentially be omitted in the absence of unexplained cytopenias. Further validation in larger prospective cohorts is warranted before broad implementation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyLymphoma, Extranodal NK-T-CellBone MarrowHumansFemaleMaleMiddle AgedRetrospective StudiesBiopsyAdultAgedNeoplasm StagingSensitivity and SpecificityPrognosisYoung Adult

Stichwörter der Autor:innen

Bone marrow biopsyHemophagocytic lymphohistiocytosisNK/T-cell lymphomaPET/CTPrognosis

Autor:innen und Institutionen

  • Department of Hematology, Jiangsu Province Hospital, the First Affiliated Hospital With Nanjing Medical University, Nanjing 210029, Jiangsu, China (H.L., Y.Z., X.W., L.C., R.W., Y.M., H.Z., J.L., L.C., L.F.).
  • Department of Nuclear Medicine, Jiangsu Province Hospital, the First Affiliated Hospital With Nanjing Medical University, Nanjing 210029, Jiangsu, China (C.D.).
  • Department of Hematology, Jiangsu Province Hospital, the First Affiliated Hospital With Nanjing Medical University, Nanjing 210029, Jiangsu, China (H.L., Y.Z., X.W., L.C., R.W., Y.M., H.Z., J.L., L.C., L.F.); Key Labora…
  • Department of Hematology, Jiangsu Province Hospital, the First Affiliated Hospital With Nanjing Medical University, Nanjing 210029, Jiangsu, China (H.L., Y.Z., X.W., L.C., R.W., Y.M., H.Z., J.L., L.C., L.F.). Electronic…

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Jiangsu Province
  • Nanjing Medical University

Zitieren

APA

Liu, H., Zhao, Y., Wang, X., Chen, L., Ding, C., Wang, R., Miao, Y., Zhu, H., Li, J., Cao, L., & Fan, L. (2025). Limited Benefit of Bone Marrow Biopsy in Extranodal NK/T-Cell Lymphoma in the PET/CT Era. Academic Radiology. https://doi.org/10.1016/j.acra.2025.09.024

Vancouver

Liu H, Zhao Y, Wang X, Chen L, Ding C, Wang R, et al. Limited Benefit of Bone Marrow Biopsy in Extranodal NK/T-Cell Lymphoma in the PET/CT Era. Academic Radiology. 2025. doi:10.1016/j.acra.2025.09.024

BibTeX
@article{Liu2025,
  author = {Liu, Hailing and Zhao, Yuxiao and Wang, Xiran and Chen, Lvwen and Ding, Chongyang and Wang, Rong and Miao, Yi and Zhu, Huayuan and Li, Jianyong and Cao, Lei and Fan, Lei},
  title = {Limited Benefit of Bone Marrow Biopsy in Extranodal NK/T-Cell Lymphoma in the PET/CT Era},
  journal = {Academic Radiology},
  year = {2025},
  doi = {10.1016/j.acra.2025.09.024}
}
Kostenlos starten →